SCHEMBL11901604

SCHEMBL11901604

BrCc1nc2ccccc2n1-c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.56
HTT P42858 1/20 0.56
TSHR P16473 2/20 0.49
PDE10A Q9Y233 1/20 0.48
POLB P06746 1/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
USP2 O75604 1/20 0.46
NTRK1 P04629 1/20 0.45
NTRK2 Q16620 1/20 0.45
RECQL P46063 2/20 0.44
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
PRKACA P17612 1/20 0.43
RPS6KB1 P23443 1/20 0.43
GSK3B P49841 1/20 0.43
ROCK1 Q13464 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
LMNA P02545 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL426154 0.82 MAPK1 (0.56) MAPK1HTTTSHRPDE10APOLB
SCHEMBL259639 0.82 MEN1 (0.58) MAPK1HTTTSHRPDE10APOLB
SCHEMBL11901939 0.82 TSHR (0.56) MAPK1HTTTSHRPDE10APOLB
SCHEMBL762447 0.82 MAPK1 (0.66) MAPK1HTTTSHRPDE10APOLB
SCHEMBL15064152 0.81 MAPK1 (0.54) MAPK1HTTTSHRPDE10APOLB
SCHEMBL15081856 0.81 MAPK1 (0.54) MAPK1HTTTSHRPDE10APOLB
SCHEMBL8022032 0.81 NPC1 (0.65) MAPK1HTTTSHRMEN1KMT2A
SCHEMBL15081854 0.81 MAPK1 (0.54) MAPK1HTTTSHRPDE10APOLB
SCHEMBL8021385 0.79 MAPT (0.59) MAPK1HTTTSHRPDE10APOLB
SCHEMBL10897524 0.78 MAPK1 (0.51) MAPK1HTTTSHRPDE10APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
EP-2673269-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2013-12-18 EP disclosed
WO-2012107465-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 WO disclosed
WO-2012107465-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 WO disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 MAPK1 71/4885HTT 4398/4885TSHR 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.